[go: up one dir, main page]

ECSP22081150A - Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica - Google Patents

Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica

Info

Publication number
ECSP22081150A
ECSP22081150A ECSENADI202281150A ECDI202281150A ECSP22081150A EC SP22081150 A ECSP22081150 A EC SP22081150A EC SENADI202281150 A ECSENADI202281150 A EC SENADI202281150A EC DI202281150 A ECDI202281150 A EC DI202281150A EC SP22081150 A ECSP22081150 A EC SP22081150A
Authority
EC
Ecuador
Prior art keywords
epidemic
prevention
treatment
infectious disease
rna viral
Prior art date
Application number
ECSENADI202281150A
Other languages
English (en)
Inventor
Hyun Kyu Chung
Geum Sil Cho
Chung Ju
Jei Man Ryu
Original Assignee
Shin Poong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shin Poong Pharmaceutical Co Ltd filed Critical Shin Poong Pharmaceutical Co Ltd
Publication of ECSP22081150A publication Critical patent/ECSP22081150A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona a un uso de pironaridina o una sal farmacéuticamente aceptable de la misma, y/o artemisinina o un derivado de la misma para la prevención o tratamiento de una enfermedad infecciosa viral de ARN epidémica, y más específicamente, a una composición farmacéutica para la prevención o tratamiento de una enfermedad infecciosa viral de ARN epidémica, en particular, Enfermedad de Coronavirus 2019 (COVID-19), la composición que comprende una cantidad terapéuticamente efectiva de pironaridina o una sal farmacéuticamente aceptable de la misma, y/o artemisinina o un derivado de la misma, junto con un portador farmacéuticamente aceptable.
ECSENADI202281150A 2020-03-26 2022-10-24 Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica ECSP22081150A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20200037135 2020-03-26

Publications (1)

Publication Number Publication Date
ECSP22081150A true ECSP22081150A (es) 2023-02-28

Family

ID=77892085

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202281150A ECSP22081150A (es) 2020-03-26 2022-10-24 Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica

Country Status (20)

Country Link
US (1) US12485116B2 (es)
EP (1) EP4129290B1 (es)
JP (1) JP2023519277A (es)
KR (2) KR102828536B1 (es)
CN (1) CN115666572B (es)
AU (1) AU2021244009A1 (es)
BR (1) BR112022019198A2 (es)
CA (1) CA3172672A1 (es)
CL (1) CL2022002588A1 (es)
CO (1) CO2022014992A2 (es)
CR (1) CR20220508A (es)
EC (1) ECSP22081150A (es)
ES (1) ES3040436T3 (es)
IL (1) IL296721A (es)
MX (1) MX2022011885A (es)
PE (1) PE20230041A1 (es)
PH (1) PH12022552516A1 (es)
PL (1) PL4129290T3 (es)
UA (1) UA130231C2 (es)
WO (1) WO2021194290A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111803491A (zh) * 2020-07-24 2020-10-23 中国人民解放军军事科学院军事医学研究院 青蒿素类化合物在治疗冠状病毒感染方面的应用
WO2022076565A1 (en) * 2020-10-07 2022-04-14 Sorrento Therapeutics, Inc. Salicylanilide analogs for use in the treatment of coronavirus
WO2023172065A1 (ko) * 2022-03-08 2023-09-14 주식회사 위바이오트리 니클로사마이드 또는 이의 약학적으로 허용 가능한 염을 포함하는 항 바이러스용 또는 항암용 조성물 및 이의 제조방법
CN116966178B (zh) * 2022-04-29 2025-10-03 成都贝诺科成生物科技有限公司 一种氨基硝基噻唑衍生物在制备预防和治疗病毒感染及其引起的相关疾病的药物中的用途
WO2025153638A1 (en) * 2024-01-19 2025-07-24 Pamoja Therapeutics Bv Highly concentrated liquid aqueous pyronaridine formulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19843222A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
WO2004071506A1 (en) 2003-02-12 2004-08-26 Georgetown University Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections
US20110206636A1 (en) * 2003-09-16 2011-08-25 Kemin Foods, LLC Use of Endoperoxides for the Treatment of Infections Caused by Flaviviridae, Including Hepatitis C, Bovine Viral Diarrhea and Classical Swine Fever Virus
KR100623322B1 (ko) 2004-11-02 2006-09-19 신풍제약주식회사 경구투여용 항말라리아 배합 제제 및 그의 제조방법
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
CN101857613B (zh) 2010-06-03 2012-04-18 中国科学院新疆理化技术研究所 一枝蒿酮酸糖酯类衍生物及其制备方法和用途
CN101898966B (zh) 2010-07-15 2013-04-17 中国科学院新疆理化技术研究所 含哌嗪环的一枝蒿酮酸酯类衍生物及其制备方法
JP5750274B2 (ja) * 2011-02-15 2015-07-15 株式会社ブリヂストン ゴムクローラ
US9675582B2 (en) 2011-10-25 2017-06-13 U.S. Phytotherapy, Inc. Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the Zika virus
US20140011829A1 (en) 2012-07-06 2014-01-09 Robert Lewis Steele Artemisinin-Based Combination Therapy For Treating Viral Mediated Disease
CN105168500B (zh) 2015-09-11 2018-08-17 青岛大学附属医院 一种用于治疗小儿口腔溃疡的药物组合物及其制备方法
US11696914B1 (en) * 2019-11-06 2023-07-11 Collaborations Pharmaceuticals, Inc. Use of pyronaridine, tilorone, and quinacrine against Marburg virus and other virus infections
EP4121041A4 (en) 2020-03-18 2024-04-03 GMP Biotechnology Limited TGF-BETA INHIBITION, AGENTS AND COMPOSITION FOR IT

Also Published As

Publication number Publication date
PL4129290T3 (pl) 2025-10-13
CA3172672A1 (en) 2021-09-30
CR20220508A (es) 2023-04-25
CN115666572B (zh) 2025-03-28
IL296721A (en) 2022-11-01
BR112022019198A2 (pt) 2022-11-16
EP4129290A1 (en) 2023-02-08
PE20230041A1 (es) 2023-01-10
WO2021194290A1 (ko) 2021-09-30
US20230132036A1 (en) 2023-04-27
US12485116B2 (en) 2025-12-02
KR102828536B1 (ko) 2025-07-02
UA130231C2 (uk) 2025-12-24
KR20240108337A (ko) 2024-07-09
ES3040436T3 (en) 2025-10-30
AU2021244009A1 (en) 2022-10-27
CL2022002588A1 (es) 2023-05-26
CN115666572A (zh) 2023-01-31
EP4129290C0 (en) 2025-07-09
KR20210120891A (ko) 2021-10-07
EP4129290B1 (en) 2025-07-09
JP2023519277A (ja) 2023-05-10
CO2022014992A2 (es) 2022-11-29
MX2022011885A (es) 2022-10-21
KR102910416B1 (ko) 2026-01-14
PH12022552516A1 (en) 2022-11-07
EP4129290A4 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
ECSP22081150A (es) Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica
CO2023000199A2 (es) Péptidos funcionalizados como agentes antivirales
UY39529A (es) Nuevos agentes antivirales derivados de espiropirrolidina
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
UY29868A1 (es) Nucleocidos 4 modificados como agentes antivirales
CO2023002852A2 (es) Péptidos funcionalizados como agentes antivirales
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
BR112012000287B8 (pt) composição farmacêutica para um inibidor de protease viral de hepatite c
CL2024000593A1 (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento...
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
BRPI0514425A (pt) inibidores de rna polimerase dependente de rna do vìrus da hepatite c, e composições e tratamentos usando os mesmos
BRPI0507628A (pt) composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
UY27466A1 (es) Métodos y composiciones para el tratamiento de hepatitis c virus con 4'-modificaciones nucleosides
ECSP11011065A (es) Composición farmacéutica de un potente inhibidor de hcv para su administración oral
AR062453A1 (es) Metodo de terapia combinada para el tratamiento de la infeccion por el virus de la hepatitis c y composiciones farmaceuticas para usar en dicha terapia
CR8220A (es) Composicion de fexofenadina y proceso para su preparacion
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
MX2022009776A (es) Tratamiento de la colangitis biliar primaria con elafibranor.
AR048336A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
UY39864A (es) Nuevos agentes antivirales derivados de espiropirrolidina
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
MX2025013861A (es) Compuestos anti virus de la inmunodeficiencia humana (vih)